Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
Aims Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI)
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
[HTML][HTML] Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
R Wachter, SJ Shah, MR Cowie, P Szecsödy… - ESC Heart …, 2020 - ncbi.nlm.nih.gov
Aims Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI)
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
R Wachter, SJ Shah, MR Cowie… - ESC Heart …, 2020 - scholars.northwestern.edu
Aims: Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI)
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.
R Wachter, SJ Shah, MR Cowie, P Szecsödy… - ESC Heart …, 2020 - europepmc.org
Aims Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI)
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
R Wachter, SJ Shah, MR Cowie, P Szecsödy… - ESC Heart …, 2020 - search.proquest.com
Aims Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI)
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
R Wachter, SJ Shah, MR Cowie, P Szecsödy, V Shi… - 2020 - pubmed.ncbi.nlm.nih.gov
Aims Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI)
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
[引用][C] Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
R Wachter, SJ Shah, MR Cowie, P Szecsödy… - 2020 - publications.goettingen-research …
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.
R Wachter, SJ Shah, MR Cowie, P Szecsödy… - ESC Heart …, 2020 - europepmc.org
Aims Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI)
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
R Wachter, SJ Shah, MR Cowie, P Szecsödy… - ESC Heart …, 2020 - search.proquest.com
Aims Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI)
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …